Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Lung Cancer.

Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, Huang M, Levy P

doi: 10.1016/j.lungcan.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Lancet.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G, KEYNOTE-042 Investigators

doi: 10.1016/S0140-6736(18)32409-7.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

J Clin Oncol.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR

doi: 10.1200/JCO.18.00149.

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Lung, Respiratory and Thoracic Cancer

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407

J Thorac Oncol.

Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Parra HS, Mazières J, Hermes B, Cicin I, Medgyasszay B, Cid JR, Okamoto I, Lee S, Ramlau R, Vladimirov V, Cheng Y, Deng X, Zhang Y, Bas T, Piperdi B, Halmos B

doi: 10.1016/j.jtho.2020.06.015.

Lung, Respiratory and Thoracic Cancer

Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer

Future Oncol.

Solomon BJ, Zhou CC, Drilon A, Park K, Wolf J, Elamin Y, Davis HM, Soldatenkova V, Sashegyi A, Lin AB, Lin BK, F Loong HH, Novello S, Arriola E, Pérol M, Goto K, Santini FC

doi: 10.2217/fon-2020-0935.

Lung, Respiratory and Thoracic Cancer

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C

doi: 10.1001/jamaoncol.

Lung, Respiratory and Thoracic Cancer

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

Ann Oncol.

Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM

doi: 10.1093/annonc/mdz288.

Lung, Respiratory and Thoracic Cancer

Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer

J Thorac Oncol

Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, Mocci S, Enquist I, Komatsubara K, McCleland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst RS

doi: 10.1016/j.jtho.2021.06.019

Related content

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Recent Developments in Metastatic Breast Cancer

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407

Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer